Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.
MK-8931 is Merck's novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research. The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.
All American Investor
If you don't see the video go here.
- What is Alzheimer's Disease? What are the Eight Types of Dementia?
- What is the Difference Between Alzheimer’s and Dementia
- Test Your Memory for Alzheimer's (5 Best Tests)
- Problems with Balance, Walking, Falling Can Be an Early Sign of Dementia
- Majority of Adults Fear Alzheimer's Disease, Want Greater Effort to Defeat It
- Is Coconut Oil a Treatment for Alzheimer's Disease?
- Urinary Tract Infections Can Hasten Memory Loss in Alzheimer's Patients
Original content Bob DeMarco, All American Investor